Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX – Get Free Report)’s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.42 and traded as low as $0.40. Eagle Pharmaceuticals shares last traded at $0.9150, with a volume of 16,118 shares changing hands.
Eagle Pharmaceuticals Price Performance
The stock has a market cap of $9.74 million, a PE ratio of 0.64 and a beta of 0.83. The stock has a 50-day simple moving average of $0.55 and a 200-day simple moving average of $0.43.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Woodcliff Lake, New Jersey, that focuses on the development, manufacturing and commercialization of hospital-administered therapies in the areas of critical care, oncology and rare diseases. Founded in 2007, Eagle has built expertise in complex injectable formulations and orphan drug designation, aiming to address unmet medical needs through both novel products and reformulated generics.
The company’s marketed portfolio in the United States includes Bendeka®, an intravenous formulation of bendamustine for certain types of leukemia and lymphoma; Beleodaq®, approved for relapsed or refractory peripheral T-cell lymphoma; and Empaveli®, a complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.
Recommended Stories
- Five stocks we like better than Eagle Pharmaceuticals
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
